{"id":47564,"date":"2026-07-30T00:04:00","date_gmt":"2026-07-29T22:04:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=81fcc0d7a6e76e76504019532e235cb6"},"modified":"2026-07-30T00:04:00","modified_gmt":"2026-07-29T22:04:00","slug":"replimune-group-inc-repl-shareholders-who-lost-money-contact-law-offices-of-howard-g-smith-about-securities-fraud-investigation","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=47564","title":{"rendered":"Replimune Group Inc. (REPL) Shareholders Who Lost Money \u2013 Contact Law Offices of Howard G. Smith About Securities Fraud Investigation"},"content":{"rendered":"

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Replimune Group Inc. (\u201cReplimune\u201d or the \u201cCompany\u201d) (NASDAQ: REPL<\/a>) investors concerning the Company\u2019s possible violations of federal securities laws.<\/p>

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REPLIMUNE GROUP INC. (REPL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.<\/b><\/p>

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com<\/a>, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com<\/a>.<\/p>

What Happened?<\/b><\/p>

On July 28, 2026, the US Food and Drug Administration (\u201cFDA\u201d) released briefing documents related to Replimune\u2019s lead trial for its drug vusolimogene oderparepvec, or RP1, for skin cancer. The briefing documents state the FDA has deemed the single-arm mid-stage study submitted by Replimune to support the approval of the drug as \"not interpretable.\" The assessment used in the study \u201cconfounds interpretation of the reported efficacy results and limits FDA\u2019s ability to verify the reported results,\u201d the FDA reviewers said.<\/p>

On this news, Replimune\u2019s stock price fell $3.27, or 37.89% in intraday trading on July 28, 2026, thereby injuring investors.<\/p>

Contact Us To Participate or Learn More:<\/b><\/p>

If you purchased Replimune Group Inc. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:<\/p>

Law Offices of Howard G. Smith,3070 Bristol Pike, Suite 112,Bensalem, Pennsylvania 19020,Telephone: (215) 638-4847Email: howardsmith@howardsmithlaw.com<\/a>,Visit our website at: www.howardsmithlaw.com<\/a>.<\/p>

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

Contact Us:<\/b>Law Offices of Howard G. SmithHoward G. Smith, Esquire215-638-4847howardsmith@howardsmithlaw.com<\/a>www.howardsmithlaw.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

BENSALEM, Pa.–(BUSINESS WIRE)–Law Offices of Howard G. Smith announces an investigation on behalf of Replimune Group Inc. (\u201cReplimune\u201d or the \u201cCompany\u201d) (NASDAQ: REPL) investors concerning the Company\u2019s possible violations of federal securities laws….<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-47564","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/47564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47564"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/47564\/revisions"}],"predecessor-version":[{"id":47565,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/47564\/revisions\/47565"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}